Table 3. Univariable Cox regression analysis for OS in EC patients treated with ICI.
AMolecular subtyping n=434 patients, excluding 3 with POLE. BPre-treatment abdominal CT scans were available for 500 patients. Reference alludes to reference group for the analysis. BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; CPNH/TP53abn, copy number-high/TP53abnormal; CNL/NSMP, copy number-low/no specific molecular profile; MSI-H, microsatellite instability high; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.
| Baseline characteristic | Variables | Univariable HR (95% CI) | p value |
|---|---|---|---|
| BMI (kg/m 2 ) | Normal (reference) | 1 | |
| Overweight | 0.61 (0.45 – 0.83) | 0.0018 | |
| Obese | 0.65 (0.49 – 0.86) | 0.0026 | |
| Age (years) | 1.01 (1.00 – 1.03) | 0.15 | |
| Self-reported race | White (reference) | 1 | |
| Asian | 0.98 (0.63 – 1.5) | 0.9 | |
| Black | 0.93 (0.65 – 1.3) | 0.66 | |
| Other | 0.96 (0.63 – 1.47) | 0.85 | |
| Histology | Endometrioid low grade (reference) | 1 | |
| Endometrioid high grade | 1.69 (1.1 – 2.6) | 0.018 | |
| Serous | 2.35 (1.65 – 3.34) | < 0.0001 | |
| Mixed/high-grade NOS | 2.17 (1.44 – 3.27) | 0.0002 | |
| Carcinosarcoma | 3.36 (2.22 – 5.1) | < 0.0001 | |
| Clear cell | 1.7 (0.89 – 3.3) | 0.1 | |
| Un-/dedifferentiated | 2.9 (1.47 – 5.78) | 0.0021 | |
| Checkpoint inhibitor | Pembrolizumab (reference) | 1 | |
| Durvalumab | 1.28 (0.96 – 1.7) | 0.09 | |
| Nivolumab | 1.38 (0.75 – 2.53) | 0.3 | |
| Other | 0.46 (0.11 – 1.84) | 0.27 | |
| Combination therapies | Lenvatinib/pembrolizumab (reference) | 1 | |
| Tremelimumab/durvalumab | 1.38 (0.94 – 2.02) | 0.1 | |
| ICI alone | 0.67 (0.51 – 0.88) | 0.004 | |
| Other combination | 1.52 (0.62 – 3.7) | 0.36 | |
| ECOG Performance Status | 0 (reference) | 1 | |
| 1 | 1.5 (1.18 – 1.92) | 0.001 | |
| 2–3 | 9.72 (5.84 – 16.19) | < 0.0001 | |
| Stage at diagnosis | 1,2 (reference) | 1 | |
| 3,4 | 1.43 (1.11 – 1.83) | 0.005 | |
| Previous lines of therapy | 0 (reference) | 1 | |
| 1 | 2.28 (1.12 – 4.65) | 0.023 | |
| 2 | 2.63 (1.27 – (5.44) | 0.009 | |
| ≥3 | 4.04 (1.92 – 8.49) | 0.0002 | |
| Previous pelvic radiotherapy | No (reference) | 1 | |
| Yes | 0.73 (0.58 – 0.92) | 0.008 | |
| Molecular Subtype A | MSI-H | 1 | |
| CN-H/TP53abn | 2.84 (1.92 – 4.22) | < 0.0001 | |
| CN-L/NSMP | 2.28 (1.44 – 3.63) | 0.0005 | |
| VAT (cm 2 ) B | Low (≤112 cm2) (reference) | 1 | |
| High (>112 cm2) | 0.73 (0.57 – 0.93) | 0.01 | |
| SAT (cm 2 ) B | Low (≤270 cm2) (reference) | 1 | |
| High (>270 cm2) | 0.79 (0.62 – 1) | 0.054 |